169 results about "Intestinal bacteria" patented technology

The invention relates to the technical field of functional microorganism screening and application, and particularly provides a strain of lactobacillus plantarum and an application of the lactobacillus plantarum in improvement of intestinal inflammation and repair of intestinal mucosa injury. The plant lactobacillus is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) on August 1, 2024, the address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the plant lactobacillus is CGMCC No.31521. The strain has remarkable antioxidant, bacteriostatic and anti-inflammatory effects, can repair intestinal barrier injury of mice with colitis, promote renewal of intestinal stem cells, promote growth of intestinal beneficial bacteria and inhibit proliferation of harmful bacteria, can be widely applied to prevention and treatment of enteritis, and has a wide market prospect.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention discloses a kit for gene detection of intestinal bacteria and a use method, and relates to the technical field of gene detection.The kit comprises a detection box, a storage plate and a test tube rack are arranged in the detection box, the test tube rack is circular, detection test tubes are annularly distributed on the test tube rack in an inserted mode, and the test tube rack is connected with a space installation mechanism and a positioning mechanism; a reagent filling mechanism and a centrifugal posture control mechanism are arranged on the storage plate, the space installation mechanism comprises a first positioning ball fixedly connected with the bottom support, the center of the test tube rack is installed in cooperation with the outer ring of the first positioning ball, a plurality of arc-shaped racks are annularly distributed on the edge, matched with the test tube rack, of the storage plate, and arc-shaped sliding grooves are formed in the arc-shaped racks; the test tube rack and the arc-shaped sliding groove are installed in a sliding mode, the test tube rack is further connected with a rotation driving assembly, multi-angle centrifugal control over the detection test tubes is achieved through the rotation driving assembly and the centrifugal posture control mechanism, and the mixing effect of florae and reagents in the detection test tubes is effectively improved.

The invention discloses a capsule robot for collecting intestinal flora and a control method of the capsule robot. The capsule robot comprises a capsule robot body and a rotatable collecting module installed in the capsule robot body. A collecting port is formed in the capsule robot body, a plurality of collecting cabins are formed in the rotating face of the collecting module, and the collecting module rotates to enable the collecting cabins to be communicated with or not communicated with the collecting port. The capsule robot is small in size and capable of achieving the flora sampling function at the same time, all the assemblies are compactly integrated in the capsule robot, the cross contamination problem between different detection parts and different collection cabins is avoided through structural design and certain sealing treatment, a control circuit is a small-size control panel, and the control circuit is simple in structure and convenient to operate. According to the capsule robot, circuit layout and space utilization are optimized, the size is reduced, meanwhile, functional integrity is guaranteed, remote non-contact collection in the body of a patient can be achieved through Bluetooth communication wireless control, and the capsule robot has the long-acting power management capacity.

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The present invention provides a sleep-aiding probiotic goat milk powder and a preparation method thereof. Goat milk is used as a raw material, the goat milk is sterilized and then cooled, and the fermented mucus lactobacillus (Limosilactobacillus fermentum) KD6 producing a sleep-aiding functional factor-γ-aminobutyric acid is accessed, which has been preserved in the China Center for Type Culture Collection on September 7, 2023, and its preservation number is CCTCC NO: M20231642. After stirring evenly, it is fermented at a constant temperature without adding glutamic acid or sodium glutamate, the precursor of γ-aminobutyric acid, etc., and the fermentation is completed to obtain probiotic fermented goat milk containing γ-aminobutyric acid, and then it is vacuum-low-temperature spray-dried to obtain functional probiotic goat milk powder that can help sleep. The sleep-aiding probiotic goat milk powder prepared by the present invention is rich in γ-aminobutyric acid and probiotics, and has the dual functions of helping sleep and regulating the balance of intestinal flora.

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

The present invention discloses a method for feeding black soldier fly larvae with a selenium-rich bacteria solution, as follows: inoculating an intestinal bacteria seed liquid of black soldier fly to a fermentation medium at an inoculum size of 1%-3%, and cultivating at 30° C.-37° C. till the log phase to obtain a fermentation broth of log phase; adding sodium selenite to the fermentation broth of log phase to enable the fermentation broth to have a sodium selenite concentration of 10-600 μg / mL, then cultivating the fermentation broth at 30° C.-37° C. for 24-36 h to obtain a selenium-rich bacteria solution; and selecting 4-to-6-day-old black soldier fly larvae to be fed, adding the selenium-rich bacteria solution to a feed to enable the feed to have a selenium content of 5-500 mg / kg (wet weight), feeding the black soldier fly larvae with the feed till the end of the fifth instar of the larvae.

The invention belongs to the field of biological medicine, and particularly relates to bifidobacterium bifidum and application of the bifidobacterium bifidum in eye health products, and the bifidobacterium bifidum BB00 has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34389. The invention further discloses a preparation method of the bifidobacterium bifidum. The bifidobacterium bifidum BB00 can improve clinical symptoms of xerophthalmia, increase tear secretion amount, prolong tear film rupture time, reduce ocular surface disease indexes, relieve corneal epithelium injury, adjust the opening degree of palpebral fissure, adjust intestinal flora composition, improve flora diversity and inhibit growth of intestinal pathogenic bacteria. The bifidobacterium bifidum BB00 not only provides an innovative solution for a clinical pain point of xerophthalmia and realizes synergistic intervention of intestinal regulation and eye health, but also has scientific innovation, clinical effectiveness and industrialization potential, and has important value for application of bacteria and fungicide in the field of biological medicine and treatment of ocular surface-intestinal tract related diseases.

The present invention belongs to the field of biotechnology and pharmaceutical engineering technology, and discloses a functionalized drug-loaded exosome based on milk exosomes, a preparation method thereof, and an application thereof. The functionalized drug-loaded exosomes include a carrier and a water-insoluble drug, and the water-insoluble drug is loaded inside the carrier; wherein the surface of the carrier is loaded with milk exosomes with functionalized molecules, and the functionalized molecule is any one of phosphatidylserine, a molecule capable of macrophage targeting, and a molecule or polymer that enhances the targeting and stability of milk exosomes; the water-insoluble drug is any one of an antibacterial drug, an antitumor drug, and a gene drug. The functionalized drug-loaded exosomes in the present invention can improve the gastrointestinal stability of oral administration and enhance the efficacy against bacterial pathogens; expand the application scope of milk exosomes in the fields of anti-intestinal bacterial infection and food preservation, and the exosome content in milk is very rich, which is convenient for large-scale preparation and has important application value.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The present invention relates to a composition for alleviating obesity, improving cognitive function and memory, and preventing Alzheimer's disease, comprising a fermented hemp seed product as an active ingredient. The fermented hemp seed product prepared by inoculating a Pediococcus acidilactici OHSI1 strain (deposit number: KCTC 15831BP) strain, of the present invention, has the effects of: increasing the abundance and diversity of intestinal microorganisms; increasing beneficial intestinal bacteria; reducing harmful intestinal bacteria; alleviating intestinal microbial flora imbalance; anti-obesity; antioxidation; and controlling Alzheimer's disease-associated enzyme activity, and thus can be effectively used as a food composition or a pharmaceutical composition for preventing, alleviating, or treating obesity or cognitive dysfunction, and as a health functional food composition for improving memory and cognitive function by improving intestinal microbial flora.

To provide a technique for reducing the count of bacteria involved in mucin decomposition within the intestine, wherein the present invention allows inhibition of growth of intestinal microbes such as Ruminococcus gnavus, which can be involved in mucin degradation; and thus, it becomes possible to reduce mucin degradation within the intestine, thereby preserving the intestinal barrier function, and contributing to the maintenance or enhancement of host health.SOLUTION: Provided is an agent that comprises agaro-oligosaccharides as an active ingredient to inhibit the growth of intestinal bacteria having, in genomic DNA, a NanA gene composed of a DNA sequence having at least 45.6% sequence identity to Sequence No. 1 (NanA gene of Ruminococcus gnavus).SELECTED DRAWING: Figure 1

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

As regards the beneficial intestinal bacteria present in the intestines of each individual, to provide a method for screening, by a simple, safe in vitro test, probiotics and prebiotics that promote the proliferation of beneficial intestinal bacteria.　A screening method according to the present invention screens probiotics or prebiotics that promote the proliferation of beneficial intestinal bacteria present in the intestine of a subject or a test animal and comprises a step for adding a fecal sample collected from a subject or a test animal and a candidate probiotic or a candidate prebiotic to a liquid culture medium and culturing anaerobically, and a step for evaluating the state of proliferation of the beneficial intestinal bacteria in the liquid culture medium after anaerobic culture. The liquid culture medium used for anaerobic culture is prepared so that the concentration of the constituent components of the liquid culture medium is 1 / 3 to 1 / 6 of the concentration normally used in the culture of beneficial intestinal bacteria.

The invention discloses a method for separating and detecting new intestinal bacterial exovesicles, which comprises the following steps: (1) carrying out metabolism labeling on microorganisms to be researched by an azido-modified hydrochloric acid D-type amino acid metabolism marker, so that the new intestinal bacterial exovesicles carry azido groups; (2) separating and extracting the bacterial exovesicles from a sample containing the bacterial exovesicles; (3) adding a capture connector capable of reacting with an azide group into the extracted bacterial outer vesicles; and (4) separating, capturing and detecting the bacterial outer vesicles obtained in the step (3) by adopting a micro-fluidic chip, wherein the obtained bacterial outer vesicles are newborn bacterial outer vesicles. The method disclosed by the invention can selectively capture the newborn bacterial exovesicles from the sample under the condition of not influencing surface protein expression of the bacterial exovesicles so as to carry out downstream analysis on the newborn bacterial exovesicles of the intestinal flora.

The invention relates to the technical field of comprehensive treatment of agricultural pests, and particularly provides a bactrocera cucurbitae double-trapping type attractant based on optimal matching of host and intestinal bacteria volatile matters and application of the bactrocera cucurbitae double-trapping type attractant. The attractant comprises an active component and a synergistic component, the active component is derived from balsam pear and towel gourd volatile matters and bactrocera cucurbitae intestinal bacterial metabolites, and comprises 2-methyl ethyl valerate, propyl hexanoate, ethyl hexadienoate, heptanal, benzyl alcohol, 3-methyl acetic acid-1-butanol, indole and 1-undecanol; and the synergistic component is myzobenzoic ketone. Active components are quickly released in the early stage of application, so that the attraction efficiency is remarkably improved; the synergistic component prolongs the trapping lasting period through the slow release effect, and the long-term trapping effect is ensured. All the components of the attractant provided by the invention are biological sources or environment-friendly chemical substances, the attractant meets the requirement of green prevention and control, can efficiently attract male and female adults at the same time, makes up the limitation that a traditional sex attractant only induces male adults or a food attractant only induces female adults, and is beneficial to more comprehensive control of population quantity.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The utility model relates to the technical field of culture medium shunting, in particular to an intestinal bacterium enrichment liquid culture medium self-flowing racking machine which is characterized in that when the racking machine is used, a plurality of groups of culture bottles are respectively placed on a bottle carrying assembly, and then the bottle carrying assembly is placed on a supporting table and is positioned and fixed through two groups of positioning assemblies; then liquid adding operation is conducted on the multiple sets of culture bottles through the flow dividing assembly, after liquid adding is completed, a worker integrally moves the multiple sets of culture bottles through the bottle carrying assembly, then the other set of bottle carrying assembly is placed and positioned, and the liquid adding efficiency is improved; comprising a supporting table, supporting legs and a liquid storage tank, the multiple sets of supporting legs are arranged at the bottom end of the supporting table, the liquid storage tank is installed at the top end of the supporting table, the distribution assembly is arranged at the output end of the liquid storage tank, the bottle carrying assembly is used for transferring multiple sets of culture bottles, and the two sets of positioning assemblies are symmetrically arranged at the top end of the supporting table.

To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6

This invention provides a multi-omics diagnostic model for inflammatory bowel disease (IBD), along with its biomarker screening method, applications, and reagent kits. Currently, there is no gold standard for diagnosing IBD, leading to many unidentifiable suspected cases in clinical practice. This invention utilizes information on the abundance of gut bacteria, the functional genes of gut bacteria, and the content of intestinal metabolites to establish a predictive model for IBD. Furthermore, this invention integrates the above two types of omics information and the prediction across three information dimensions to establish a predictive model with impressive predictive capabilities. The method and model of this invention can assist in the diagnosis and differentiation of IBD.

The invention discloses bactrocera cucurbitae intestinal bacterium compound bacteria and application thereof, and relates to the technical field of biology. The bacterial compound bacteria comprise the providencia rettgeri M15 and the providencia mantanoxydans M52, the preservation number of the providencia rettgeri M15 is CGMCC (China General Microbiological Culture Collection Center) 1.62474, and the preservation number of the providencia mantanoxydans M52 is CGMCC 1.62475. The invention further discloses a preparation method of the bacterial compound bacteria, and the bacterial compound bacteria comprise the providencia rettgeri M15 and the providencia mantanoxydans M52. The compound bacteria are mainly used for improving the survival rate of bactrocera cucurbitae larvae.

A toilet system according to an embodiment of the present invention comprises: a first detection sensor that is provided to a toilet device and detects odorless gas; a second detection sensor that is provided to the toilet device and detects odorous gas; and an estimation means for estimating, on the basis of detection results from the first detection sensor and the second detection sensor, at least one of the intestinal bacteria, metabolites of intestinal bacteria, or pH of a user who uses the toilet device.

The invention discloses a phosphoric acid compound capable of resisting intestinal bacterial adhesion as well as a preparation method and application of the phosphoric acid compound, and belongs to the technical field of foods and medicines. The phosphoric acid compound is prepared from an amino-rich compound, a solution containing a phosphate compound with the mass concentration being 3% or above, a solution containing a zinc compound with the mass concentration being 3% or above, glucomannan, an alkaline solution and water. The phosphoric acid compound can effectively inhibit the adhesion of bacteria to intestinal mucosa, can control the probability of intestinal bacteria invasion, reduce the occurrence probability of intestinal leakage, control chronic inflammation in the body, can solve the intestinal health problem caused by the adhesion of intestinal bacteria, and plays an important role. In order to ensure the safety of the product and not introduce reagents and substances harmful to health, the used preparation process and production process are simple and easy to industrially amplify, harmful substances are prevented from being generated in the production process, the operation is easy, and large-scale production can be realized.

The invention relates to the technical field of coprophilous fungus transplantation, in particular to an intestinal fungus capsule and a preparation process thereof. The preparation process comprises the following steps: preparing the fecal fungi; adding a special freeze-drying protective agent and then carrying out freeze-drying treatment; and filling the freeze-dried bacterial powder into a capsule to prepare the intestinal bacterial capsule. The freeze-drying protective agent comprises the following raw materials: cane sugar, whey protein, mannitol, trehalose, lecithin, vitamin C and water. By optimizing a freeze-drying protective agent formula and an accurate freeze-drying process, the freeze-drying survival rate of thalli is remarkably improved, and a test result shows that the survival rate of probiotics such as bifidobacterium and lactic acid bacteria exceeds 90%. The capsule form is adopted to ensure that thalli are accurately released in the intestinal tract, discomfort and thalli loss caused by a traditional transplantation mode are avoided, and the storage stability is effectively improved.

The present invention provides a donor-recipient matching model for enterobacteria transplantation and a method for constructing the same. By combining donor and recipient information, the donor-recipient matching model is successfully constructed through metagenomic sequencing, meta-analysis, and neural network modeling. The model is applied to clinical experiments for performance comparison and evaluation of the reliability of the model, verifying the feasibility of the model prepared by the present invention and can be successfully applied to the treatment of gynecological diseases.

The invention relates to the technical field of biological medicines, in particular to application of intestinal probiotics and metabolites thereof in treating autism spectrum disorders. According to the application disclosed by the invention, six intestinal bacteria which are in causal negative correlation with ASD are identified for the first time from the perspective of genetics, and the effects of ruminococcus gavreuii of the ruminococcus and the effects of Satasella wadsworensis of the ruminococcus on the autism spectrum disorder are verified. The invention also discloses a kit for detecting the autism spectrum disorder of the Autism spectrum disorder and a kit for detecting the autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder. Experiments prove that the traditional Chinese medicine composition can significantly improve social defects of model mice and has no side effects on normal mice. The invention provides new targets and candidate substances for developing probiotic preparations, metabolite supplements or functional foods for preventing, relieving or treating ASD, and has important clinical application prospects.

A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ / β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ / δ) is preferably 8.8 or less.

This invention discloses a method for the synergistic metabolic analysis of multiple components of traditional Chinese medicine (TCM) integrated with the gut microbiota. After initializing the microbiota ecosystem, a solution of multi-component TCM extracts is continuously injected into a microfluidic chip. Stable isotope-labeled precursors are pulsed into a specific simulation region to perform spatial isotope encoding. A standing wave acoustic field is applied at the sampling node of the microfluidic chip, and multiphase fluid spatial splitting is performed using the difference in the primary acoustic radiation force experienced by the particles to derive cell-free TCM metabolites. The cell-free TCM metabolites are separated by chromatography and gas phase drift separation. A four-dimensional metabolic feature array is constructed, and the absolute value of the mass shift is calculated for spatial inverse decoding. Closed-loop feedback is triggered based on the rate of change of target metabolite ion abundance, increasing the amplitude of the standing wave acoustic field pressure to confine intestinal bacteria and performing in-situ enrichment of synergistic metabolic intermediates. This invention realizes the spatial metabolic trajectory tracing and network reconstruction of multiple components of TCM in a complex gut microbiota ecosystem.

A use of intestinal bacteria that co-produce D-lactate and a metabolite thereof D-lactate in predicting exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate affect the levels of the exercise-related hormones dopamine and adrenaline, thereby significantly impairing exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate are markers that can be used for routine exercise monitoring and for regulating exercise tolerance.